Enhanced Ozempic Dosage Surpasses Mounjaro Switch in Cardiovascular Protection
A groundbreaking real-world study has caught the attention of health and wellness communities worldwide. The study suggests that increasing the dosage of Ozempic (semaglutide) might provide superior heart protection compared to switching to its competitor, Mounjaro (tirzepatide). This revelation could have a profound impact on the millions of individuals managing type 2 diabetes.
The study, conducted by Novo Nordisk’s COMPETE SWITCH Cardiovascular (CV) study, was unveiled at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. The retrospective analysis was based on insurance claims data from a staggering 636,525 adults with type 2 diabetes. The results indicated that patients who increased their Ozempic dose from 1 mg to 2 mg weekly had a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) — including death from any cause, heart attack, and stroke — compared to those who switched to Mounjaro at doses up to 15 mg.
On October 5, 2026, Healthline cautioned that the results should be interpreted carefully as the study was observational, showing association rather than direct causation. However, Michael Radin, MD, executive medical director at Novo Nordisk, believes the data could assist healthcare professionals in making more informed decisions for patients already on semaglutide therapy. This study introduces a critical new perspective to the ongoing discussion surrounding two of the world’s most frequently prescribed diabetes and weight-loss medications.
Source: Healthline – Increasing Ozempic Dose Linked to Lower Heart Risk Than Switching to Mounjaro